Journal article icon

Journal article

Clinical development of Modified Vaccinia virus Ankara vaccines.

Abstract:

The smallpox vaccine Vaccinia was successfully used to eradicate smallpox, but although very effective, it was a very reactogenic vaccine and responsible for the deaths of one or two people per million vaccinated. Modified Vaccinia virus Ankara (MVA) is a replication-deficient and attenuated derivative, also used in the smallpox eradication campaign and now being developed as a recombinant viral vector to produce vaccines against infectious diseases and cancer. Many clinical trials of these n...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Medicine, Jenner Institute
Journal:
Vaccine
Volume:
31
Issue:
39
Pages:
4241-4246
Publication date:
2013-09-05
DOI:
EISSN:
1873-2518
ISSN:
0264-410X
URN:
uuid:21f0393c-8a8b-459f-9a01-415d8a9ca55b
Source identifiers:
390839
Local pid:
pubs:390839

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP